SEZL:NASDAQSezzle Inc. Analysis
Data as of 2026-07-18 - not real-time
$174.67
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Sezzle’s price is comfortably above its short‑term and mid‑term moving averages and sits well above the long‑term trend line, underscoring a strong bullish bias. Momentum indicators such as the RSI sit in a neutral‑to‑slightly‑overbought zone, while the MACD has turned bearish, hinting at a possible short‑term pullback. The stock trades above a solid support tier yet remains below a clear resistance ceiling that aligns with recent highs. Volatility is elevated and beta is markedly high, amplifying price swings. Fundamental metrics reveal a price‑to‑earnings multiple that far exceeds the sector average and a discounted cash‑flow estimate that suggests the market price is materially above intrinsic value. The upside‑downside assessment points to a modest downside potential, and the market sentiment index is in the extreme greed territory. Recent coverage downgraded the stock on valuation grounds after a spectacular year‑to‑date rally, adding pressure on the near‑term price path. Despite these concerns, the company posts impressive gross, operating and profit margins, and generates strong cash flow from operations. Return on equity is exceptionally high, reflecting efficient capital use. The business model benefits from recurring subscription revenues and expanding installment‑payment adoption in North America. Overall, the technical picture is bullish but tempered by valuation and short‑term indicator warnings, while the fundamentals remain robust.
Investors should weigh the high valuation against the company’s superior profitability and cash generation. The elevated beta and volatility suggest that price moves could be sharp, especially if broader market sentiment shifts. The downgrade and lofty valuation may limit upside in the medium horizon, but the durable earnings power could support a longer‑term hold. Caution is warranted given the overvalued metrics, yet the underlying growth narrative provides a catalyst for eventual re‑rating if the market re‑aligns with fundamentals.
Investors should weigh the high valuation against the company’s superior profitability and cash generation. The elevated beta and volatility suggest that price moves could be sharp, especially if broader market sentiment shifts. The downgrade and lofty valuation may limit upside in the medium horizon, but the durable earnings power could support a longer‑term hold. Caution is warranted given the overvalued metrics, yet the underlying growth narrative provides a catalyst for eventual re‑rating if the market re‑aligns with fundamentals.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- price above key moving averages
- bearish MACD crossover
- recent downgrade on valuation
Medium Term
1–3 yearsCautious
Model confidence: 7/10
Key Factors
- price trading far above discounted cash‑flow estimate
- high valuation multiples versus peers
- elevated volatility and beta
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- exceptional operating margins and cash flow generation
- strong return on equity
- growth potential in installment‑payment market
Key Metrics & Analysis
Financial Health
Revenue Growth29.20%
Profit Margin30.83%
P/E Ratio43.0
ROE91.95%
ROA47.54%
Debt/Equity73.79
P/B Ratio29.8
Op. Cash Flow$246.4M
Free Cash Flow$72.5M
Industry P/E17.8
Technical Analysis
TrendBullish
RSI57.1
Support$147.33
Resistance$195.71
MA 20$171.62
MA 50$137.17
MA 200$86.29
MACDBearish
VolumeStable
Fear & Greed Index87.91
Valuation
Fair Value$76.00
Target Price$163.67
Upside/Downside-6.30%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta2.36
Volatility82.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.